Endocrinology Medical News about Diabetes

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study
The Lancet - Early Online Publication, 06/15/09

Henry RR et al. – Short-term clinical data show a favorable safety and efficacy profile for the dual peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonist aleglitazar.

Methods

SYNCHRONY study: double-blind study to establish glucose-lowering and lipid-modifying effects and safety profile of aleglitazar
Enrollment of type 2 diabetes pts (either drug-naive or pre-treated with ≤2 oral agents) from 47 sites in 7 countries
Single-blind, placebo run-in period of 4-5 wks
Randomization of 332 pts double-blind to 16 wk-treatment with aleglitazar at once-daily doses of 50, 150, 300, or 600, or matching placebo (55 pts in each group), or to open-label pioglitazone 45 mg once daily (57 pts) as a reference
Primary efficacy endpoint: change in glycosylated hemoglobin (HbA1c) concentration from baseline to treatment end
Efficacy analysis of pts who received ≥1 dose of study drug and had ≥1 evaluable post-baseline HbA1c measurement

Results

Aleglitazar significantly reduced baseline HbA1c vs placebo in a dose-dependent manner
Trend of changes over time suggests that maximum effect of aleglitazar on HbA1c concentration not yet reached after 16 wks of treatment
Edema, hemodilution, and weight gain occurred in a dose-dependent manner
At aleglitazar doses <300 microg, no pts had congestive heart failure, similar frequency to placebo for edema and less than with pioglitazone, and bodyweight gain was less than with pioglitazone

<< Previous
Adhering to a Tai Chi Program to Improve Glucose Control and...

Next >>
Elevated aldosterone levels in patients with androgenetic...